Safety and immunogenicity of bivalent RSVpreF vaccine formulated in a multidose vial in healthy female participants in the USA: a multicentre, randomised, open-label, noninferiority phase 3 studyResearch in context

Summary: Background: Bivalent respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVpreF) is currently available as a preservative-free, single-dose vial (SDV) presentation. RSVpreF offered in a multidose vial (MDV) may help reduce vaccination costs in lower-middle-income countries (LMI...

Ful tanımlama

Detaylı Bibliyografya

Asıl Yazarlar:	Uzma N. Sarwar, Jeffrey B. Baker, Lisa Pereira, Barbara A. Pahud, Jon Finley, David Strong, Sandra Pagnussat, Shyam Patel, Yanping Liu, Emma Shittu, Olympia Evdoxia Anastasiou, Elena V. Kalinina, Kena A. Swanson, Annaliesa S. Anderson, Alejandra Gurtman, Iona Munjal
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Elsevier 2026-02-01
Seri Bilgileri:	EClinicalMedicine
Konular:	Immunogenicity LMIC Multidose vial RSV RSVpreF Safety
Online Erişim:	http://www.sciencedirect.com/science/article/pii/S2589537026000143
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!